Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given

Pasadena-based Arrowhead Pharmaceuticals, Inc. announced on Tuesday that Chief Operating Officer Dr. Bruce Given has retired.

Given’s career spanned more than 30-years in biotechnology and pharmaceutical research, development, and sales and marketing. 

“Bruce had an impressive and successful career and Arrowhead benefited enormously from his leadership of our R&D organization since 2011,” Arrowhead Pharmaceuticals President and CEO Chris Anzalone said in a statement. “Together with the rest of the Arrowhead team, I would like to thank Bruce and wish him our best during his retirement.”

The company said Dr. Javier San Martin, chief medical officer; Dr. Curt Bradshaw, chief scientific officer; and James Hassard, chief commercial officer, will assume Dr. Given’s areas of responsibility. They will report directly to the CEO. 

Dr. Given will be retained in an advisory capacity for a period of at least one year, the company said. 

Arrowhead Pharmaceuticals specializes in developing medicines that treat intractable diseases by gene silencing, or RNA interference (RNAi). RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein.

For more information on the company and their RNAi-based therapeutics, visit www.arrowheadpharma.com.